These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 38471995)

  • 1. [Pembrolizumab in adjuvant therapy in non-small cell lung cancers].
    Lefèvre A; Tissot C
    Bull Cancer; 2024 Apr; 111(4):334-336. PubMed ID: 38471995
    [No Abstract]   [Full Text] [Related]  

  • 2. [Prolonged response with paclitaxel after immunotherapy by pembrolizumab in lung cancer].
    Zapata E; Mennecier B; Leduc C; Chatron E; Quoix E
    Rev Pneumol Clin; 2016 Oct; 72(5):300-304. PubMed ID: 27561974
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Nivolumab, a new hope in non-small cell lung cancer].
    Flippot R; Fallet V; Besse B; Massard C; Wislez M; Vignot S
    Bull Cancer; 2015 Dec; 102(12):1046-52. PubMed ID: 26585939
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Not Available].
    Fabre E; Pécuchet N; Cadranel J
    Bull Cancer; 2016 Nov; 103 Suppl 1():S138-S143. PubMed ID: 28057177
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Ipilimumab-nivolumab as first-line treatment in metastatic NSCLC].
    El-Ghazzi N; Lavaud P
    Bull Cancer; 2021 Mar; 108(3):231-233. PubMed ID: 33622569
    [No Abstract]   [Full Text] [Related]  

  • 6. [Atezolizumab in a first-line setting in non-small-cell lung cancer with high PD-L1 expression].
    Roulleaux Dugage M; Brosseau S
    Bull Cancer; 2021 Oct; 108(10):904-906. PubMed ID: 34598788
    [No Abstract]   [Full Text] [Related]  

  • 7. Indirect comparison between pembrolizumab and nivolumab for the treatment of non-small cell lung cancer: A meta-analysis of randomized clinical trials.
    Peng TR; Tsai FP; Wu TW
    Int Immunopharmacol; 2017 Aug; 49():85-94. PubMed ID: 28554108
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Unexpected adverse events of immunotherapies in non-small cell lung cancer: About 2 cases].
    de Chabot G; Justeau G; Pinquié F; Nadaj-Pakleza A; Hoppé E; Hureaux J; Urban T
    Rev Pneumol Clin; 2017 Dec; 73(6):326-330. PubMed ID: 29169677
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative efficacy and safety of immunotherapies targeting the PD-1/PD-L1 pathway for previously treated advanced non-small cell lung cancer: A Bayesian network meta-analysis.
    Almutairi AR; Alkhatib N; Martin J; Babiker HM; Garland LL; McBride A; Abraham I
    Crit Rev Oncol Hematol; 2019 Oct; 142():16-25. PubMed ID: 31326706
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Perioperative treatment for resected non-small cell lung cancer: Which option in 2020?].
    Coureau M; Berghmans T
    Rev Mal Respir; 2021 Jan; 38(1):74-86. PubMed ID: 33402250
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-world comparison of immune checkpoint inhibitors in non-small cell lung cancer following platinum-based chemotherapy.
    Weis TM; Hough S; Reddy HG; Daignault-Newton S; Kalemkerian GP
    J Oncol Pharm Pract; 2020 Apr; 26(3):564-571. PubMed ID: 31238808
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [A Reflection of the New Wave of Immunotherapy on the Clinical Study of 
Chinese Lung Cancer Immunotherapy].
    Liu J; Zhang S; Li S; Cheng Y
    Zhongguo Fei Ai Za Zhi; 2017 Oct; 20(10):695-702. PubMed ID: 29061217
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Retreatment with pembrolizumab in advanced non-small cell lung cancer patients previously treated with nivolumab: emerging reports of 12 cases.
    Fujita K; Uchida N; Kanai O; Okamura M; Nakatani K; Mio T
    Cancer Chemother Pharmacol; 2018 Jun; 81(6):1105-1109. PubMed ID: 29675747
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characteristics of Real-World Metastatic Non-Small Cell Lung Cancer Patients Treated with Nivolumab and Pembrolizumab During the Year Following Approval.
    Khozin S; Abernethy AP; Nussbaum NC; Zhi J; Curtis MD; Tucker M; Lee SE; Light DE; Gossai A; Sorg RA; Torres AZ; Patel P; Blumenthal GM; Pazdur R
    Oncologist; 2018 Mar; 23(3):328-336. PubMed ID: 29317551
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Drug approval: ATEZOLIZUMAB as monotherapy in NSCLC PD-L1 ≥ 50%, without EGFR mutation or ALK rearrangement, for adjuvant treatment after complete surgery and platinum-based chemotherapy].
    Boudier B; Aldea M
    Bull Cancer; 2023 Apr; 110(4):337-338. PubMed ID: 36803981
    [No Abstract]   [Full Text] [Related]  

  • 16. Economic Burden of Checkpoint Inhibitor Immunotherapy for the Treatment of Non-Small Cell Lung Cancer in US Clinical Practice.
    Nesline MK; Knight T; Colman S; Patel K
    Clin Ther; 2020 Sep; 42(9):1682-1698.e7. PubMed ID: 32747004
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness and safety of atezolizumab, nivolumab and pembrolizumab in metastatic non-small cell lung cancer.
    Burgos-San José A; Colomer-Aguilar C; Martínez-Caballero D; Massutí-Sureda B
    Farm Hosp; 2021 Apr; 45(3):121-125. PubMed ID: 33941055
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Advances in the Treatment of Non-small Cell Lung Cancer: Focus on Nivolumab, Pembrolizumab, and Atezolizumab.
    Leventakos K; Mansfield AS
    BioDrugs; 2016 Oct; 30(5):397-405. PubMed ID: 27411930
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Interest of focal radiotherapy in case of oligoprogression under immunotherapy in the treatment of metastatic non-small cell lung cancer].
    Gagé A; Pereira B; Belliere A; Janicot H; Jeannin G; Bourrachot C; Durand M; Rolland-Debord C; Merle P
    Bull Cancer; 2023 Dec; 110(12):1234-1243. PubMed ID: 38445648
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prediction of the Therapeutic Effects of Pembrolizumab and Nivolumab in Advanced Non-Small Cell Lung Cancer by Platelet-Derived Microparticles in Circulating Blood.
    Liu T; Wang J; Liu Y; Wu J; Yuan Y; Wang C; Fang X; Li H
    Technol Cancer Res Treat; 2021; 20():1533033821997817. PubMed ID: 33612078
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.